Bayer Returns to Gene Therapy Arena with Dimension Therapeutics Deal
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 8 (Table of Contents)
Published: 11 Aug-2014
DOI: 10.3833/pdr.v2014.i8.2050 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Less than a year after its launch in 2013, Dimension Therapeutics has secured its first big pharma partner by agreeing to collaborate with Bayer to develop and commercialise a preclinical-stage gene therapy programme for haemophilia A...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018